Format

Send to

Choose Destination
Dermatol Clin. 2017 Apr;35(2):257-265. doi: 10.1016/j.det.2016.11.014.

Vitiligo Pathogenesis and Emerging Treatments.

Author information

1
Department of Dermatology, University of Massachusetts Medical School, Worcester, MA 01605, USA; Department of Dermatology, Tehran University of Medical Sciences, 415 Taleqani Avenue, Tehran 1416613675, Iran.
2
Department of Dermatology, University of Massachusetts Medical School, Worcester, MA 01605, USA. Electronic address: John.Harris@umassmed.edu.

Abstract

The pathogenesis of vitiligo involves interplay between intrinsic and extrinsic melanocyte defects, innate immune inflammation, and T-cell-mediated melanocyte destruction. The goal of treatment is to not only halt disease progression but also promote repigmentation through melanocyte regeneration, proliferation, and migration. Treatment strategies that address all aspects of disease pathogenesis and repigmentation are likely to have greatest efficacy, a strategy that may require combination therapies. Current treatments generally involve nontargeted suppression of autoimmunity, whereas emerging treatments are likely to use a more targeted approach based on in-depth understanding of disease pathogenesis, which may provide higher efficacy with a good safety profile.

KEYWORDS:

Autoimmunity; Cellular stress; Chemokines; Melanogenesis; Targeted therapy; Vitiligo

PMID:
28317534
PMCID:
PMC5362109
DOI:
10.1016/j.det.2016.11.014
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center